AcTor/IXZ was equally potent in a <i>TP53</i>-mutated patient-derived xenograft model, exceeding the efficacy of standard-of-care.<h4>Conclusions</h4>As a TSC2 inhibitor, AcTor should not be used alone in cancer. Here, TP53 is linked to cancer.